v0.07 🌳  

Investment Firms Provide Consensus Rating for Informa plc (LON:INF)

2024-06-15 08:54:03.539000

Connor Clark & Lunn Investment Management Ltd. has made two new investments in Fabrinet (FN) and OmniAb, Inc. (OABI) [3a507848] [de4bfe4f].

Rosenblatt has initiated coverage of Fabrinet (FN) with a buy recommendation [35223a33]. The average price target for FN is $168.04, representing a decrease of 3.49% from the latest closing price of $174.12. The price target range is $130.29 to $210.00 [35223a33]. Institutional ownership of FN has decreased by 1.09% in the last three months, with a total of 43,355K shares owned by institutions. The top institutional holder owns 2,545K shares, which represents 7.03% ownership [35223a33]. Fabrinet is a leading provider of advanced optical packaging and manufacturing services for various industries. They have a broad range of capabilities and facilities in multiple countries [35223a33].

Connor Clark & Lunn Investment Management Ltd. has purchased 13,372 shares of Fabrinet (NYSE:FN) in the 3rd quarter, valued at approximately $2,228,000 [de4bfe4f]. Other large investors have also recently bought and sold shares of FN. Fabrinet reported $1.89 EPS for the quarter, beating analysts' estimates of $1.84. The stock has a market capitalization of $7.41 billion, a P/E ratio of 29.47, and a beta of 1.06. Insiders own 0.51% of the company's stock [de4bfe4f].

Connor Clark & Lunn Investment Management Ltd. has also purchased a new stake in OmniAb, Inc. (NASDAQ:OABI) worth $1.19 million. The firm purchased 229,455 shares of the company's stock, representing approximately 0.20% ownership. Other hedge funds and institutional investors have also added or reduced their stakes in OABI. OmniAb is a biotechnology company that provides therapeutic antibody discovery technologies in the United States [3a507848].

Gabelli & Co Investment Advisers Inc. has bought a new position in shares of Olink Holding AB (publ) (NASDAQ:OLK) in the fourth quarter, purchasing 116,843 shares valued at approximately $2,939,000. Other hedge funds and institutional investors also recently bought and sold shares of OLK. Gabelli Funds LLC acquired a new stake in shares of Olink Holding AB (publ) during the 4th quarter valued at approximately $9,513,000. Gardner Lewis Asset Management L P purchased a new stake in Olink Holding AB (publ) during the fourth quarter worth $10,403,000. Carmignac Gestion acquired a new stake in Olink Holding AB (publ) in the fourth quarter valued at $3,104,000. Assetmark Inc. increased its position in shares of Olink Holding AB (publ) by 30.5% in the fourth quarter, and UBS Group AG increased its position in shares of Olink Holding AB (publ) by 5,531.1% in the fourth quarter. Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focus on life science research. The company's products include Olink Explore, Olink Target, Olink Flex, and Olink Focus. The stock has a 1-year low of $14.10 and a 1-year high of $26.01. Olink Holding AB (publ) last announced its earnings results on May 13th, reporting a negative EPS of ($0.13) for the quarter. Analysts forecast that Olink Holding AB will post -0.19 earnings per share for the current fiscal year.

Informa plc (LON:INF) has been given a consensus recommendation of 'Moderate Buy' by the seven ratings firms that are covering the firm. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is GBX 865.33 ($11.02). Informa plc operates as an international events, digital services, and academic knowledge company in the United Kingdom, Continental Europe, North America, China, and internationally. It operates through four segments: Informa Markets, Informa Tech, Informa Connect, and Taylor & Francis. The Informa Connect segment delivers specialist content, and live events and on-demand experiences for professionals through in-person, live, and digital platforms and services that enables businesses and professionals to meet, network, discuss, and learn.

Disclaimer: The story curated or synthesized by the AI agents may not always be accurate or complete. It is provided for informational purposes only and should not be relied upon as legal, financial, or professional advice. Please use your own discretion.